Edward Gabrielson

List of Publications by Year
in descending order

118 papers	18,338 citations	20759 60 h-index	21474 114 g-index
120 all docs	120 docs citations	120 times ranked	25378 citing authors

#	Article	IF	Citations
1	NRF2 Activation Promotes Aggressive Lung Cancer and Associates with Poor Clinical Outcomes. Clinical Cancer Research, 2021, 27, 877-888.	3.2	84
2	Animal Models of Prenatal Stress. Juntendo Medical Journal, 2021, 67, 124-130.	0.1	1
3	CRYÎ²B2 enhances tumorigenesis through upregulation of nucleolin in triple negative breast cancer. Oncogene, 2021, 40, 5752-5763.	2.6	6
4	Pharmacodynamic measures within tumors expose differential activity of PD(L)-1 antibody therapeutics. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	3.3	21
5	Biguanide drugs enhance cytotoxic effects of cisplatin by depleting aspartate and NAD+ in sensitive cancer cells. Cancer Biology and Therapy, 2021, 22, 579-586.	1.5	4
6	Multimodal genomic features predict outcome of immune checkpoint blockade in non-small-cell lung cancer. Nature Cancer, 2020, 1, 99-111.	5.7	141
7	Proteomic Analysis of the Air-Way Fluid in Lung Cancer. Detection of Periostin in Bronchoalveolar Lavage (BAL). Frontiers in Oncology, 2020, 10, 1072.	1.3	4
8	Concurrent Targeting of Potential Cancer Stem Cells Regulating Pathways Sensitizes Lung Adenocarcinoma to Standard Chemotherapy. Molecular Cancer Therapeutics, 2020, 19, 2175-2185.	1.9	8
9	Proteomic signatures of 16 major types of human cancer reveal universal and cancer-type-specific proteins for the identification of potential therapeutic targets. Journal of Hematology and Oncology, 2020, 13, 170.	6.9	25
10	DNA methylation markers predict recurrence-free interval in triple-negative breast cancer. Npj Breast Cancer, 2020, 6, 3.	2.3	15
11	Compartmental Analysis of T-cell Clonal Dynamics as a Function of Pathologic Response to Neoadjuvant PD-1 Blockade in Resectable Nonâ€“Small Cell Lung Cancer. Clinical Cancer Research, 2020, 26, 1327-1337.	3.2	90
12	Expression of p16 and p53 in non-small-cell lung cancer: clinicopathological correlation and potential prognostic impact. Biomarkers in Medicine, 2019, 13, 761-771.	0.6	19
13	DNA Methylation Markers for Breast Cancer Detection in the Developing World. Clinical Cancer Research, 2019, 25, 6357-6367.	3.2	21
14	A Computational Model of Neoadjuvant PD-1 Inhibition in Non-Small Cell Lung Cancer. AAPS Journal, 2019, 21, 79.	2.2	53
15	Uncovering the Role of N-Acetyl-Aspartyl-Glutamate as a Glutamate Reservoir in Cancer. Cell Reports, 2019, 27, 491-501.e6.	2.9	73
16	Prognostic Impact of Phosphorylated Discoidin Domain Receptor-1 in Esophageal Cancer. Journal of Surgical Research, 2019, 235, 479-486.	0.8	6
17	Dynamics of Tumor and Immune Responses during Immune Checkpoint Blockade in Nonâ€“Small Cell Lung Cancer. Cancer Research, 2019, 79, 1214-1225.	0.4	226
18	Detection of RAS and RAS-associated alterations in primary lung adenocarcinomas. A correlation between molecular findings and tumor characteristics. Human Pathology, 2019, 84, 18-25.	1.1	5

#	Article	IF	Citations
19	Peptide-based PET quantifies target engagement of PD-L1 therapeutics. Journal of Clinical Investigation, 2019, 129, 616-630.	3.9	94
20	A Randomized Phase II Study of Metformin plus Paclitaxel/Carboplatin/Bevacizumab in Patients with Chemotherapy-NaÃ¯ve Advanced or Metastatic Nonsquamous Non-Small Cell Lung Cancer. Oncologist, 2018, 23, 859-865.	1.9	73
21	Neoadjuvant PD-1 Blockade in Resectable Lung Cancer. New England Journal of Medicine, 2018, 378, 1976-1986.	13.9	1,495
22	Nrf2 signaling and autophagy are complementary in protecting breast cancer cells during glucose deprivation. Free Radical Biology and Medicine, 2018, 120, 407-413.	1.3	39
23	Chemotherapy induces enrichment of CD47 ⁺ /CD73 ⁺ /PDL1 ⁺ immune evasive triple-negative breast cancer cells. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, E1239-E1248.	3.3	238
24	Added Value of Computer-aided CT Image Features for Early Lung Cancer Diagnosis with Small Pulmonary Nodules: A Matched Case-Control Study. Radiology, 2018, 286, 286-295.	3.6	118
25	Unique pulmonary immunotoxicological effects of urban PM are not recapitulated solely by carbon black, diesel exhaust or coal fly ash. Environmental Research, 2018, 161, 304-313.	3.7	26
26	Current WHO guidelines and the critical role of immunohistochemical markers in the subclassification of non-small cell lung carcinoma (NSCLC): Moving from targeted therapy to immunotherapy. Seminars in Cancer Biology, 2018, 52, 103-109.	4.3	534
27	De novo lipogenesis represents a therapeutic target in mutant Kras nonâ€small cell lung cancer. FASEB Journal, 2018, 32, 7018-7027.	0.2	33
28	Quantitative phosphoproteomic analysis reveals reciprocal activation of receptor tyrosine kinases between cancer epithelial cells and stromal fibroblasts. Clinical Proteomics, 2018, 15, 21.	1.1	15
29	C3a is required for ILC2 function in allergic airway inflammation. Mucosal Immunology, 2018, 11, 1653-1662.	2.7	32
30	Heterogeneous expression of PD-L1 in pulmonary squamous cell carcinoma and adenocarcinoma: implications for assessment by small biopsy. Modern Pathology, 2017, 30, 530-538.	2.9	92
31	The critical role of EBUSâ€TBNA cytology in the staging of mediastinal lymph nodes in lung cancer patients: A correlation study with positron emission tomography findings. Cancer Cytopathology, 2017, 125, 717-725.	1.4	25
32	Evolution of Neoantigen Landscape during Immune Checkpoint Blockade in Nonâ€“Small Cell Lung Cancer. Cancer Discovery, 2017, 7, 264-276.	7.7	706
33	Chronic Cigarette Smoke-Induced Epigenomic Changes Precede Sensitization of Bronchial Epithelial Cells to Single-Step Transformation by KRAS Mutations. Cancer Cell, 2017, 32, 360-376.e6.	7.7	162
34	The non-receptor tyrosine kinase TNK2/ACK1 is a novel therapeutic target in triple negative breast cancer. Oncotarget, 2017, 8, 2971-2983.	0.8	42
35	Hypoxia-inducible factors regulate pluripotency factor expression by ZNF217- and ALKBH5-mediated modulation of RNA methylation in breast cancer cells. Oncotarget, 2016, 7, 64527-64542.	0.8	215
36	Detection of <scp>PIK3CA</scp> mutations, including a novel mutation of <scp>V344G</scp> in exon 4, in metastatic lung adenocarcinomas: A retrospective study of 115 <scp>FNA</scp> cases. Cancer Cytopathology, 2016, 124, 485-492.	1.4	6

#	Article	IF	Citations
37	Utility of a novel triple marker (combination of thyroid transcription factor 1, Napsin A, and P40) in the subclassification of nonâ€“small cell lung carcinomas using fine-needle aspiration cases. Human Pathology, 2016, 54, 8-16.	1.1	14
38	Epsteinâ€“Barr Virus Infection of Mammary Epithelial Cells Promotes Malignant Transformation. EBioMedicine, 2016, 9, 148-160.	2.7	61
39	Small Molecule Inhibitor of NRF2 Selectively Intervenes Therapeutic Resistance in KEAP1-Deficient NSCLC Tumors. ACS Chemical Biology, 2016, 11, 3214-3225.	1.6	364
40	Expression of P40 and P63 in lung cancers using fine needle aspiration cases. Understanding clinical pitfalls and limitations. Journal of the American Society of Cytopathology, 2016, 5, 123-132.	0.2	18
41	Neoadjuvant anti-PD1, nivolumab, in early stage resectable non-small-cell lung cancer.. Journal of Clinical Oncology, 2016, 34, e20005-e20005.	0.8	1
42	Phosphoproteomic profiling of tumor tissues identifies HSP27 Ser82 phosphorylation as a robust marker of early ischemia. Scientific Reports, 2015, 5, 13660.	1.6	11
43	Epigenetic silencing of neurofilament genes promotes an aggressive phenotype in breast cancer. Epigenetics, 2015, 10, 622-632.	1.3	29
44	Utility of five commonly used immunohistochemical markers TTFâ€1, Napsin A, CK7, CK5/6 and P63 in primary and metastatic adenocarcinoma and squamous cell carcinoma of the lung: a retrospective study of 246 fine needle aspiration cases. Clinical and Translational Medicine, 2015, 4, 16.	1.7	65
45	Phosphoproteomic Analysis Identifies Focal Adhesion Kinase 2 (FAK2) as a Potential Therapeutic Target for Tamoxifen Resistance in Breast Cancer. Molecular and Cellular Proteomics, 2015, 14, 2887-2900.	2.5	26
46	TBCRC 008: Early Change in ¹⁸F-FDG Uptake on PET Predicts Response to Preoperative Systemic Therapy in Human Epidermal Growth Factor Receptor 2â€“Negative Primary Operable Breast Cancer. Journal of Nuclear Medicine, 2015, 56, 31-37.	2.8	61
47	AMP-activated kinase (AMPK) regulates activity of HER2 and EGFR in breast cancer. Oncotarget, 2015, 6, 14754-14765.	0.8	30
48	Global phosphotyrosine survey in triple-negative breast cancer reveals activation of multiple tyrosine kinase signaling pathways. Oncotarget, 2015, 6, 29143-29160.	0.8	44
49	Long Interspersed Element-1 Protein Expression Is a Hallmark of Many Human Cancers. American Journal of Pathology, 2014, 184, 1280-1286.	1.9	250
50	Activation of diverse signalling pathways by oncogenic PIK3CA mutations. Nature Communications, 2014, 5, 4961.	5.8	72
51	The utility of a novel triple marker (combination of TTF1, napsin A, and p40) in the subclassification of nonâ€“small cell lung cancer. Human Pathology, 2014, 45, 926-934.	1.1	51
52	Collective Invasion in Breast Cancer Requires a Conserved Basal Epithelial Program. Cell, 2013, 155, 1639-1651.	13.5	652
53	Aberrant Mucin5B expression in lung adenocarcinomas detected by iTRAQ labeling quantitative proteomics and immunohistochemistry. Clinical Proteomics, 2013, 10, 15.	1.1	18
54	Frequent Inactivation of Cysteine Dioxygenase Type 1 Contributes to Survival of Breast Cancer Cells and Resistance to Anthracyclines. Clinical Cancer Research, 2013, 19, 3201-3211.	3.2	77

#	Article	IF	Citations
55	Comparison of EGFR and KRAS mutations in primary and unpaired metastatic lung adenocarcinoma with potential chemotherapy effect. Human Pathology, 2013, 44, 1286-1292.	1.1	19
56	Glycoproteomic Analysis of Bronchoalveolar Lavage (BAL) Fluid Identifies Tumor-Associated Glycoproteins from Lung Adenocarcinoma. Journal of Proteome Research, 2013, 12, 3689-3696.	1.8	26
57	Very Long-Chain Acyl-CoA Synthetase 3: Overexpression and Growth Dependence in Lung Cancer. PLoS ONE, 2013, 8, e69392.	1.1	18
58	Transcription factor NRF2 regulates miR-1 and miR-206 to drive tumorigenesis. Journal of Clinical Investigation, 2013, 123, 2921-2934.	3.9	283
59	Digoxin as an inhibitor of global hypoxia inducible factor-1Î± (HIF1Î±) expression and downstream targets in breast cancer: Dig-HIF1 pharmacodynamic trial.. Journal of Clinical Oncology, 2013, 31, TPS1144-TPS1144.	0.8	2
60	Prolonged sulforaphane treatment does not enhance tumorigenesis in oncogenic K-ras and xenograft mouse models of lung cancer. Journal of Carcinogenesis, 2012, 11, 8.	2.5	14
61	Biomarkers for detection and prognosis of breast cancer identified by a functional hypermethylome screen. Epigenetics, 2012, 7, 701-709.	1.3	59
62	Application of glycoproteomics for the discovery of biomarkers in lung cancer. Proteomics - Clinical Applications, 2012, 6, 244-256.	0.8	26
63	Improvement of cellularity on cell block preparations using the soâ€called tissue coagulum clot method during endobronchial ultrasoundâ€guided transbronchial fineâ€needle aspiration. Cancer Cytopathology, 2012, 120, 185-195.	1.4	89
64	Early change in 18-fluorodeoxyglucose (FDG) uptake on positron emission tomography (PET) to predict response to preoperative systemic therapy (PST) in HER2-negative primary operable breast cancer: Translational breast cancer research consortium (TBCRC008).. Journal of Clinical Oncology, 2012, 30, 10509-10509.	0.8	3
65	EGFR and KRAS mutations in metastatic lung adenocarcinomas. Human Pathology, 2011, 42, 1447-1453.	1.1	57
66	Monitoring of neoadjuvant chemotherapy using multiparametric, 23Na sodium MR, and multimodality (PET/CT/MRI) imaging in locally advanced breast cancer. Breast Cancer Research and Treatment, 2011, 128, 119-126.	1.1	69
67	KEAP1 gene mutations and NRF2 activation are common in pulmonary papillary adenocarcinoma. Journal of Human Genetics, 2011, 56, 230-234.	1.1	89
68	High levels of the Mps1 checkpoint protein are protective of aneuploidy in breast cancer cells. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 5384-5389.	3.3	129
69	Mutation of a single allele of the cancer susceptibility gene BRCA1 leads to genomic instability in human breast epithelial cells. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 17773-17778.	3.3	134
70	Nuclear Factor-ÎºB (NF-ÎºB) Mediates a Protective Response in Cancer Cells Treated with Inhibitors of Fatty Acid Synthase. Journal of Biological Chemistry, 2011, 286, 31457-31465.	1.6	12
71	The utility of napsinâ€A in the identification of primary and metastatic lung adenocarcinoma among cytologically poorly differentiated carcinomas. Cancer Cytopathology, 2010, 118, 441-449.	1.4	93
72	Deletion of Keap1 in the Lung Attenuates Acute Cigarette Smokeâ€“Induced Oxidative Stress and Inflammation. American Journal of Respiratory Cell and Molecular Biology, 2010, 42, 524-536.	1.4	128

#	Article	IF	Citations
73	High levels of fatty acid synthase expression in esophageal cancers represent a potential target for therapy. Cancer Biology and Therapy, 2010, 10, 549-554.	1.5	26
74	DNA Methylation Markers and Early Recurrence in Stage I Lung Cancer. New England Journal of Medicine, 2008, 358, 1118-1128.	13.9	546
75	RNAi-Mediated Silencing of Nuclear Factor Erythroid-2â€"Related Factor 2 Gene Expression in Nonâ€"Small Cell Lung Cancer Inhibits Tumor Growth and Increases Efficacy of Chemotherapy. Cancer Research, 2008, 68, 7975-7984.	0.4	331
76	Inhibiting Fatty Acid Synthase for Chemoprevention of Chemically Induced Lung Tumors. Clinical Cancer Research, 2008, 14, 2458-2464.	3.2	79
77	Selective inhibition of fatty acid synthase for lung cancer treatment. Juntendoì„ Igaku, 2008, 54, 10-15.	0.1	0
78	Coix seed extract, A commonly used treatment for cancer in china, inhibits NFÎºB and protein kinase C signaling. Cancer Biology and Therapy, 2007, 6, 2005-2011.	1.5	80
79	Selective Inhibition of Fatty Acid Synthase for Lung Cancer Treatment. Clinical Cancer Research, 2007, 13, 7139-7145.	3.2	106
80	Cross-study validation and combined analysis of gene expression microarray data. Biostatistics, 2007, 9, 333-354.	0.9	46
81	FDG-PET for Pharmacodynamic Assessment of the Fatty Acid Synthase Inhibitor C75 in an Experimental Model of Lung Cancer. Pharmaceutical Research, 2007, 24, 1202-1207.	1.7	18
82	Worldwide trends in lung cancer pathology. Respirology, 2006, 11, 533-538.	1.3	124
83	Increased Expression of Mitotic Checkpoint Genes in Breast Cancer Cells with Chromosomal Instability. Clinical Cancer Research, 2006, 12, 405-410.	3.2	237
84	Dysfunctional KEAP1â€"NRF2 Interaction in Non-Small-Cell Lung Cancer. PLoS Medicine, 2006, 3, e420.	3.9	894
85	Multiple-laboratory comparison of microarray platforms. Nature Methods, 2005, 2, 345-350.	9.0	814
86	Frequent down-regulation of HIVEP2 in human breast cancer. Breast Cancer Research and Treatment, 2005, 91, 103-112.	1.1	9
87	Gene Promoter Hypermethylation in Tumors and Plasma of Breast Cancer Patients. Cancer Research and Treatment, 2005, 37, 233.	1.3	16
88	Hypermethylation of the GATA Genes in Lung Cancer. Clinical Cancer Research, 2004, 10, 7917-7924.	3.2	117
89	Hypermethylation of a Small CpGuanine-Rich Region Correlates with Loss of Activator Protein-2Î± Expression during Progression of Breast Cancer. Cancer Research, 2004, 64, 1611-1620.	0.4	67
90	A Cross-Study Comparison of Gene Expression Studies for the Molecular Classification of Lung Cancer. Clinical Cancer Research, 2004, 10, 2922-2927.	3.2	196

#	Article	IF	Citations
91	Induction of spermidine/spermine N 1-acetyltransferase in breast cancer tissues treated with the polyamine analogue N 1,N 11-diethylnorspermine. Cancer Chemotherapy and Pharmacology, 2004, 54, 122-126.	1.1	27
92	Hypermethylation in Histologically Distinct Classes of Breast Cancer. Clinical Cancer Research, 2004, 10, 5998-6005.	3.2	109
93	Telomere Shortening Occurs in Subsets of Normal Breast Epithelium as well as in Situ and Invasive Carcinoma. American Journal of Pathology, 2004, 164, 925-935.	1.9	133
94	Identification of carboxypeptidase E and Î³-glutamyl hydrolase as biomarkers for pulmonary neuroendocrine tumors by cDNA microarray. Human Pathology, 2004, 35, 1196-1209.	1.1	69
95	Clinical and Biological Relevance of Recently Defi ned Categories of Pulmonary Neoplasia. , 2003, 74, 31-42.		0
96	A neural survival factor is a candidate oncogene in breast cancer. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 10931-10936.	3.3	118
97	Molecular markers in ductal carcinoma in situ of the breast. Molecular Cancer Research, 2003, 1, 362-75.	1.5	205
98	Variable Levels of Chromosomal Instability and Mitotic Spindle Checkpoint Defects in Breast Cancer. American Journal of Pathology, 2002, 161, 391-397.	1.9	100
99	A genomic screen for genes upregulated by demethylation and histone deacetylase inhibition in human colorectal cancer. Nature Genetics, 2002, 31, 141-149.	9.4	820
100	Mucinous Cancers have Fewer Genomic Alterations than More Common Classes of Breast Cancer. Breast Cancer Research and Treatment, 2002, 76, 255-260.	1.1	36
101	Combined use of oligonucleotide and tissue microarrays identifies cancer/testis antigens as biomarkers in lung carcinoma. Cancer Research, 2002, 62, 3971-9.	0.4	100
102	Methylation of the E-cadherin Gene in Bladder Neoplasia and in Normal Urothelial Epithelium from Elderly Individuals. American Journal of Pathology, 2001, 159, 831-835.	1.9	116
103	Detection of breast cancer cells in ductal lavage fluid by methylation-specific PCR. Lancet, The, 2001, 357, 1335-1336.	6.3	324
104	Spreadsheet-Based Program for the Analysis of DNA Methylation. BioTechniques, 2001, 30, 110-114.	0.8	16
105	Doublet discrimination in DNA cell-cycle analysis. Cytometry, 2001, 46, 296-306.	1.8	168
106	Genomic imbalances in human lung adenocarcinomas and squamous cell carcinomas. Genes Chromosomes and Cancer, 2001, 31, 282-287.	1.5	101
107	Hypermethylation of 14-3-3 Ïƒ (stratifin) is an early event in breast cancer. Oncogene, 2001, 20, 3348-3353.	2.6	284
108	Functional Genomics, Gene Arrays, and the Future of Pathology. Modern Pathology, 2001, 14, 1294-1299.	2.9	25

#	Article	IF	Citations
109	Methylation Patterns of the E-cadherin 5â€² CpG Island Are Unstable and Reflect the Dynamic, Heterogeneous Loss of E-cadherin Expression during Metastatic Progression. Journal of Biological Chemistry, 2000, 275, 2727-2732.	1.6	338
110	Pancreatic Mucinous Cystic Neoplasms with Sarcomatous Stroma: Molecular Evidence for Monoclonal Origin with Subsequent Divergence of the Epithelial and Sarcomatous Components. Modern Pathology, 2000, 13, 86-91.	2.9	62
111	Promoter Hypermethylation and BRCA1 Inactivation in Sporadic Breast and Ovarian Tumors. Journal of the National Cancer Institute, 2000, 92, 564-569.	3.0	1,013
112	Spreadsheet-Based Program for Alignment of Overlapping DNA Sequences. BioTechniques, 1999, 26, 1180-1185.	0.8	6
113	Absence of intragenic mismatch mutations in small cell lung cancers with microsatellite instability. , 1999, 80, 944-945.		1
114	Methylation of the HIC-1 candidate tumor suppressor gene in human breast cancer. Oncogene, 1998, 16, 2159-2164.	2.6	137
115	Detection of frequent allelic loss of 6q23â€“q25.2 in microdissected human breast cancer tissues. , 1996, 16, 35-39.		68
116	Frequency of homozygous deletion at p16/CDKN2 in primary human tumours. Nature Genetics, 1995, 11, 210-212.	9.4	593
117	5â€² CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/CDKN2/MTS1 in human cancers. Nature Medicine, 1995, 1, 686-692.	15.2	1,812
118	Optimized Cross-Study Analysis of Microarray-Based Predictors. , 0, , 398-422.		1